Fidelity SPDR Advertisement
Home > Boards > US Listed > Medical - Drugs >

Provectus Biopharmaceuticals Inc. (PVCT)

PVCT RSS Feed
Add PVCT Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Gulfbreeze, Ovidius, buccaneer1961
Search This Board:
Last Post: 10/1/2014 4:49:12 PM - Followers: 165 - Board type: Free - Posts Today: 0

This board acts as a portal for PVCT investors, and retains the right to refuse service to individuals not in compliance with reasonable, responsible, and intelligible posting practices.




PVCT on YouTube...
http://www.youtube.com/watch?v=nuYpvcnAq4c

http://www.theze.cn/diabetes/cure-for-cancer-provectus-pharmaceutical-pv-10-for-melanoma-story-airs-on-abcs-730-report-in-australia-provectus-pharmaceutical-pvct.html


--------------------------------------------------------------
Letter from the CEO Craig Dee's

We are a group of dedicated and entrepreneurial scientists, working together for the past 10 years, engaged in developing breakthrough technologies for cancer and other serious diseases. Our primary goal at Provectus is to develop alternative treatments that are safer, more effective, less invasive and more economical than conventional therapies.

Our Provectus Pharmatech division develops ethical pharmaceuticals for oncology and dermatology. Looking first to oncology, our novel drugs are designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing systemic side effects. In particular, our focus is on melanoma, breast and liver cancers – among the most difficult cancers to treat using conventional methods. We are very excited about the Phase I clinical trials of Provecta™ that began in 2005 for melanoma and breast cancer, and we are expanding to include liver cancer patients soon.

Targeting abnormal or diseased cells is also the approach we use in designing proprietary treatments for dermatological diseases, in particular, chronic, severe cases of psoriasis, eczema and acne. We anticipate that Phase II clinical trials of our topical agent Xantryl™ for psoriasis and eczema will begin soon. In addition, certain skin cancers may be targeted and treated more safely and effectively using Xantryl™.

In addition to our core pharmaceutical work, Provectus has developed a number of intellectual properties and technologies in the areas of medical devices and biotechnologies. Rather than dilute the efforts of Pharmatech, we are actively pursuing licensure, co-development, spin-offs and joint ventures of these technologies via our divisions Provectus Devicetech and Provectus Biotech. Devicetech encompasses both cosmetic and therapeutic treatments, with key attention to developing laser-based products to treat melanoma. Biotech is concentrating on producing vaccines to prevent certain cancers and other serious diseases, as well as detecting new viruses that could be associated with the onset of such diseases.

Our fourth division, Pure-ific Corp., is prepped to be sold or spun off to further develop its over-the-counter products. We are introducing professional skincare products for disposable glove users, and novel retail products for personal hygiene. In addition, we will be introducing an OTC product for acne sufferers.

We are proud of our intellectual capital at Provectus. We hold 15 U.S. patents in the pharmaceutical, medical device and biotech fields, with 19 additional patent applications in the works.

Provectus is a significant, emerging player in the huge and growing pharmaceutical industry. We believe in our potential to improve health care worldwide, using breakthrough products that are easy to manufacture and license, and economical to use. We appreciate your interest in our company, and welcome your comments and questions.


Craig Dees, Ph.D., CEO
Provectus Pharmaceuticals
--------------------------------------------------------------


PVCT 6 months chart:
http://stockcharts.com/h-sc/ui?s=PVCT&p=D&yr=0&mn=6&dy=0&id=p03754661229

Technical analysis:
http://www.stockta.com/cgi-bin/analysis.pl?symb=PVCT&num1=7&cobrand=&mode=stock



PVCT News:
http://finance.yahoo.com/q/h?s=pvct.ob



DETAILED RESEARCH REPORTS:
--------------------------------------------------------------

http://www.pvct.com/analyst_reports.html

--------------------------------------------------------------

PVCT insiders transactions:
http://www.secform4.com/insider/showhistory.php?symbol=pvct

--------------------------------------------------------------


Drug Delivery Technology magazine special feature article "Revisiting Intralesional Delivery of Cancer Treatment", by Provectus CEO Craig Dees, Ph.D., compares Provectus’ novel cancer drugs to current cancer treatments.
http://www.pvct.com/DDTv6n2-SpecialFeature.pdf

--------------------------------------------------------------
May 17, 2007
Professor Peter Hersey, M.D. comments on PV-10 and a patient's response
Professor Peter Hersey, M.D., a professor of oncology at the University of Newcastle and Medical and Research Director of the Newcastle Melanoma Unit, comments on PV-10 and a patient's response.

Video can be viewed here.

http://www.pvct.com/hersey_pv10_video.html?pg=2

This 15-minute clip follows the progress of an 86-year-old man treated with the drug. Prior to his treatment, his melanoma was so unresponsive to the current standard of care, including numerous invasive operations and toxic chemotherapy, that he was given only months to live.

Video can be viewed here.

http://www.pvct.com/hersey_pv10_video.html?pg=5
--------------------------------------------------------------
Contact Info

Telephone: +1 (865) 769-4011
Fax: +1 (865) 769-4013
info@pvct.com

Mailing Address:
Provectus Pharmaceuticals, Inc.
7327 Oak Ridge Hwy
Knoxville, TN 37931 USA

Transfer Agent:
(i.e. stockholder records, transfer, change of address, etc.)
Atlas Stock Transfer
5899 South State Street, Suite # 24
Murray, UT 84107
Telephone: +1 (801) 266-7151
Fax: +1 (801) 262-0907

Investor Relations:
Joseph Kessler
The Investor Relations Group
11 Stone St., 3rd fl
New York, NY 10004
Telephone: 212-825-3210
Fax: 212-825-3229
jkessler@investorrelationsgroup.com

Public Relations:
The Investor Relations Group
Janet Vasquez
Telephone: 212-825-3210
janet@theinvestorrelationsgroup.com

Investment Advisor:
Damon Testaverde
Network 1 Financial Securities
Telephone: +1 (800) 205-8031
--------------------------------------------------------------
Share Statistics
Outstanding:
45.45 m
Float:
35.35 m

Non-Corp. Insider Hold'gs:
22.20% (as of 4/1/07)
--------------------------------------------------------------

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PVCT
Current Price
Volume:
Bid Ask Day's Range
Wiki
PVCT News: Current Report Filing (8-k) 05/27/2014 03:45:39 PM
PVCT News: Current Report Filing (8-k) 05/23/2014 02:19:35 PM
PVCT News: Current Report Filing (8-k) 05/21/2014 03:32:59 PM
PVCT News: Amended Statement of Changes in Beneficial Ownership (4/a) 05/20/2014 05:20:44 PM
PVCT News: Statement of Changes in Beneficial Ownership (4) 05/20/2014 06:08:15 AM
PostSubject
#3564  Sticky Note Provectus SEC Filings... Gulfbreeze 05/01/14 12:10:06 AM
#3563  Sticky Note PLEASE STICKY THIS INFORMATION laxerpro22 04/30/14 11:21:55 PM
#6625   Good price too! yaya88888888888 10/01/14 04:49:12 PM
#6624   2 interesting articles on Cancernetwork: FDA Approves Anti-PD-1 FortStCowboy 10/01/14 04:22:00 PM
#6623   Thanks Vorlon..Interesting take..especially regarding Tom:) KPS88 10/01/14 03:48:42 PM
#6622   My guess: vorlon1966 10/01/14 03:40:09 PM
#6621   Idea's on price decline given news from Spain? KPS88 10/01/14 03:18:08 PM
#6620   Buying more! yaya88888888888 10/01/14 09:55:39 AM
#6619   Novel Rose Bengal Formulation Obliterates Lesions in Patients Gulfbreeze 10/01/14 09:02:45 AM
#6618   I wouldn't think they would have signed the KPS88 09/30/14 02:09:38 PM
#6617   Is anyone concerned that PVCT will not accept big orange 09/30/14 01:29:47 PM
#6616   Taking a rest! yaya88888888888 09/30/14 01:28:08 PM
#6615   Thoughts on why such low volume? KPS88 09/30/14 12:25:50 PM
#6614   that's great news! yaya88888888888 09/30/14 12:21:23 PM
#6613   Nice to read! yaya88888888888 09/30/14 12:13:24 PM
#6612   http://melanomanewstoday.com/2014/09/18/study-shows-experimental-drug-pv-10-resu vorlon1966 09/30/14 11:34:32 AM
#6611   Brought me up to 36K overall. I KPS88 09/30/14 09:59:49 AM
#6610   Picked up 4K more this morning. KPS88 09/30/14 09:57:34 AM
#6609   awesome! good news buccaneer1961 09/30/14 01:20:59 AM
#6608   Should be hearing from the MOU within 45 Ovidius 09/30/14 01:16:06 AM
#6607   yes! perhaps a year or 2 but this buccaneer1961 09/30/14 01:05:15 AM
#6606   that's just around the corner and I like this! yaya88888888888 09/30/14 01:04:32 AM
#6605   since before the new year but waiting on buccaneer1961 09/30/14 12:54:30 AM
#6604   How long have you been with it? yaya88888888888 09/30/14 12:49:15 AM
#6603   good idea! buccaneer1961 09/30/14 12:46:19 AM
#6602   I picked up 5 this morning will get yaya88888888888 09/30/14 12:44:19 AM
#6601   If you wish to meet someone, then a vorlon1966 09/29/14 05:10:24 PM
#6600   Vorlon- Are you gonna be at Bailey's Wed or Thurs? Tasermania 09/29/14 04:35:02 PM
#6599   Low volume days lately. Ovidius 09/29/14 03:53:21 PM
#6598   PVCT chart...... 123tom 09/29/14 03:09:26 PM
#6597   Nivolumab potentially superior to standard chemo in advanced FortStCowboy 09/29/14 02:55:17 PM
#6596   the healing mentality...... 123tom 09/29/14 02:45:57 PM
#6595   So PV10 works like gang busters, plus bystander Paulness 09/29/14 02:08:25 PM
#6594   123Tom - big pharma will not touch such one_would_believe 09/29/14 01:00:36 PM
#6593   I bought 5000 shares this morning!!! yaya88888888888 09/29/14 11:58:31 AM
#6592   DCA decreases tumor by just a tiny percentage vorlon1966 09/29/14 11:47:36 AM
#6591   Interesting article about Canadian scientists discovering 123tom 09/29/14 03:56:35 AM
#6590   "Biotech reporter concedes he may be exchanging information FortStCowboy 09/28/14 10:22:19 PM
#6589   it has lots of potential 10,000 shares would buccaneer1961 09/28/14 07:04:11 PM
#6588   Maybe its a good entry here or start position? yaya88888888888 09/28/14 04:16:39 PM
#6587   Whats your opinion on this stock? I like it! yaya88888888888 09/28/14 04:15:10 PM
#6586   http://ecancer.org/news/6380-calming-down-immune-cells-could-hold-key-to-melanom FortStCowboy 09/27/14 03:49:00 PM
#6585   Back under a dollar... Blah EODparty7 09/26/14 05:49:38 PM
#6584   nah...I'm just having a chuckle... 123tom 09/25/14 04:58:35 PM
#6582   Dear Adam F... Urgent message .... 123tom 09/25/14 04:22:10 PM
#6581   Vorlon, not sure what stocks you are looking Ovidius 09/25/14 04:17:46 PM
#6580   This was not a PVCT related sell off. vorlon1966 09/25/14 04:00:34 PM
#6579   Looks like a lot of people got cured Paulness 09/25/14 03:32:23 PM
#6578   Not sure if he is under investigation but Gulfbreeze 09/24/14 08:04:17 PM
#6577   Would like CTD's take on new data. KPS88 09/24/14 04:04:26 PM
#6576   Isn't he (AF) under SEC investigation as well? FortStCowboy 09/24/14 02:26:21 PM
#6575   To make the point simpler. Replace CR with vorlon1966 09/24/14 02:08:20 PM
PostSubject